The Role of Nonrandomized Trials in the Evaluation of Oncology Drugs

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 5, 2015, Pages 502-507

  Simon, R ^a   Blumenthal, G M ^b   Rothenberg, M L ^c   Sommer, J ^d   Roberts, S A ^e   Armstrong, D K ^f   Lavange, L M ^b   Pazdur, R ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c PFIZER INC   (United States)

^d Chordoma Foundation   (United States)

^e Friends of Cancer Research   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOASSAY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; NEOPLASMS; ONCOLOGY; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84932113310     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.86     Document Type: Article

References (21)

1. Johnson, J.R., Williams, G. & Pazdur, R. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. 21, 1404–1411 (2003).
2. Stewart, D.J. & Kurzrock, R. Cancer: the road to Amiens. J. Clin. Oncol. 27 328–333 (2009).
3. Sharma, M.R. & Schilsky, R.L. Role of randomized phase III trials in an era of effective targeted therapies. Nat. Rev. Clin. Oncol. 9, 208– 214 (2012).
4. Fleming, T. et al. Development paths for new drugs with large treatment effects seen early. Conference on Clinical Cancer Research. (2011).
5. Sargent, D.J. & Hayes, D.F. Assessing the measure of a new drug: is survival the only thing that matters? J. Clin. Oncol. 26, 1922–1923 (2008).
6. Heinrich, M.C. et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin. Cancer Res. 14, 2717–2725 (2008).
7. Axelson, M. et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin. Cancer Res. 19, 2289–2293 (2013).
8. Oxnard, G.R. et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J. Natl. Cancer Inst. 104, 1534–1541 (2012).
9. Zubrod, C.G. et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J. Chronic Dis. 11, 7–33 (1960).
10. Sherrill, B., Kaye, J.A., Sandin, R., Cappelleri, J.C. & Chen, C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Oncol. Targets Ther. 5, 287–296 (2012).
11. Torri, V., Simon, R., Russek-Cohen, E., Midthune, D. & Friedman, M. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J. Natl. Cancer Inst. 84, 407–414 (1992).
12. Blumenthal, G. et al. Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): a meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. Food and Drug Administration (FDA). ASCO Annual Meeting. (2014).
13. Janku, F., Berry, D.A., Gong, J., Parsons, H.A., Stewart, D.J. & Kurzrock, R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin. Cancer Res. 18, 6356– 6363 (2012).
14. Schwartz, L. Getting the right drug to the right patient faster. ASCO Annual Meeting. <;http://meetinglibrary.asco.org/content/94975>; (2014).
15. Jain, R.K. et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J. Clin. Oncol. 30, 2684–2690 (2012).
16. .
17. Korn, E.L. & Freidlin, B. Conditional power calculations for clinical trials with historical controls. Stat. Med. 25, 2922– 2931 (2006).
18. Shaw, A.T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004– 1012 (2011).
19. Johnson, J.R., Ning, Y.M., Farrell, A., Justice, R., Keegan, P. & Pazdur, R. Accelerated approval of oncology products: the Food and Drug Administration experience. J. Natl. Cancer Inst. 103, 636–644 (2011).
20. Lovly, C., Horn, L. & Pao, W. My cancer genome: BRAF mutations in non-small cell lung cancer (NSCLC). <;http://www.mycancergenome. org/content/disease/lung-cancer/braf>; (2013).
21. Minasian, L., Rosen, O., Auclair, D., Rahman, A., Pazdur, R. & Schilsky, R.L. Optimizing dosing of oncology drugs. Clin. Pharmacol. Ther. 96, 572–579 (2014).